Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ty Erickson

Obstetrics & Gynecology Idaho Falls, ID Medical Doctor

NPI 1083783823 CMS profile 275681

808 Pancheri Drive, Idaho Falls, ID 83402

Open in the dashboard

General payments

$285,548

354 records reported · program years 2019–2025

Research payments

$167,364

Paid to them · 18 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$160,191 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Ty Erickson of Idaho Falls, ID is reported in the CMS Open Payments database as having received $285,548 across 354 general payments and $167,364 in research payments paid to them. Separately, studies naming them as principal investigator received $160,191 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $44,490 66
2024 General $50,095 68
2023 General $29,173 51
2023 Research $128,316 8
2022 General $37,344 59
2022 Research $4,500 1
2021 General $11,221 42
2020 General $29,195 32
2020 Research $4,729 3
2019 General $84,030 36
2019 Research $29,818 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ty Erickson
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Ty Erickson were reported at $44,490. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Ty Erickson Obstetrics & Gynecology median Middle half National median
2019 $84,030 $172 $62–$391 $163
2020 $29,195 $94 $36–$222 $114
2021 $11,221 $136 $42–$369 $132
2022 $37,344 $160 $50–$433 $149
2023 $29,173 $169 $56–$423 $160
2024 $50,095 $152 $50–$371 $164
2025 $44,490 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Coloplast Corp $265,924 274 payments
  2. Virtual Incision Corporation $10,280 4 payments
  3. FEMSelect Inc. $6,000 2 payments
  4. Medtronic, Inc. $1,024 19 payments
  5. Celularity, Inc. $888 6 payments
  6. AbbVie, Inc. $412 15 payments
  7. Caldera Medical, Inc $261 4 payments
  8. Medtronic USA, Inc. $247 6 payments
  9. Astellas Pharma US Inc $133 5 payments
  10. Myriad Genetic Laboratories, Inc. $72 1 payment
  11. Other $307 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $130,497 57 payments
  2. Royalty or License $55,255 2 payments
  3. Education $53,167 18 payments
  4. Travel and Lodging $36,839 94 payments
  5. Food and Beverage $9,057 181 payments
  6. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $734 2 payments
Products named General payments · program years 2019–2025
  1. Altis Women's Health $124,309 178 payments
  2. RESTORELLE $100,171 16 payments
  3. Luja Coude $20,708 6 payments
  4. Mira $10,280 4 payments
  5. NEUGUIDE $6,000 2 payments
  6. ALTIS Female Incontinence $5,719 29 payments
  7. Titan $3,976 6 payments
  8. Biovance $888 6 payments
  9. Interfyl $888 6 payments
  10. INTERSTIM $593 10 payments
  11. Other $2,827 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Coloplast Corp $167,364 18 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

276

Median for Obstetrics & Gynecology: 65

Drug cost

$28,492

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

6.2%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 17 $12,387
Estradiol Generic 214 $10,719
Solifenacin Succinate Generic 22 $4,447
Trimethoprim Generic 23 $939

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$43,268

Of which drugs: $6,082

Medicare patients

76

Average age 73

Services billed

1,684

76 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 55%
Diabetes 38%
Depression 36%
Chronic kidney disease 22%
Osteoporosis 22%
Ischemic heart disease 16%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $8
$8 — —
QULIPTA
  • AbbVie, Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

372 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Idaho

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record